
FDA cheers on Gilead's remdesivir with a snap emergency OK, giving biopharma a shot at redemption
The FDA didn’t leave much time to assess the positive nature of the first cut of data from a controlled study of remdesivir in severely afflicted coronavirus cases. On Friday the agency stamped their approval on Gilead’s drug, which NIAID director Anthony Fauci has already determined should become the new standard of care in treating hospitalized patients fighting off Covid-19.
Then on Sunday, Gilead CEO Dan O’Day took to “Face the Nation” to promise that the first 1.5 million doses of this drug — enough to treat anywhere from 100,000 to 200,000 patients — would be rushed, free of charge, to US cities where it is needed the most.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.